Literature DB >> 22547340

Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer.

Jessica Chubak1, Onchee Yu, Gaia Pocobelli, Lois Lamerato, Joe Webster, Marianne N Prout, Marianne Ulcickas Yood, William E Barlow, Diana S M Buist.   

Abstract

BACKGROUND: Studies of breast cancer outcomes rely on the identification of second breast cancer events (recurrences and second breast primary tumors). Cancer registries often do not capture recurrences, and chart abstraction can be infeasible or expensive. An alternative is using administrative health-care data to identify second breast cancer events; however, these algorithms must be validated against a gold standard.
METHODS: We developed algorithms using data from 3152 women in an integrated health-care system who were diagnosed with stage I or II breast cancer in 1993-2006. Medical record review served as the gold standard for second breast cancer events. Administrative data used in algorithm development included procedures, diagnoses, prescription fills, and cancer registry records. We randomly divided the cohort into training and testing samples and used a classification and regression tree analysis to build algorithms for classifying women as having or not having a second breast cancer event. We created several algorithms for researchers to use based on the relative importance of sensitivity, specificity, and positive predictive value (PPV) in future studies.
RESULTS: The algorithm with high specificity and PPV had 89% sensitivity (95% confidence interval [CI] = 84% to 92%), 99% specificity (95% CI = 98% to 99%), and 90% PPV (95% CI = 86% to 94%); the high-sensitivity algorithm had 96% sensitivity (95% CI = 93% to 98%), 95% specificity (95% CI = 94% to 96%), and 74% PPV (95% CI = 68% to 78%).
CONCLUSIONS: Algorithms based on administrative data can identify second breast cancer events with high sensitivity, specificity, and PPV. The algorithms presented here promote efficient outcomes research, allowing researchers to prioritize sensitivity, specificity, or PPV in identifying second breast cancer events.

Entities:  

Mesh:

Year:  2012        PMID: 22547340      PMCID: PMC3732250          DOI: 10.1093/jnci/djs233

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  21 in total

1.  Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study.

Authors:  Thomas P Ahern; Lars Pedersen; Maja Tarp; Deirdre P Cronin-Fenton; Jens Peter Garne; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash
Journal:  J Natl Cancer Inst       Date:  2011-08-02       Impact factor: 13.506

2.  Recurrences and second primary breast cancers in older women with initial early-stage disease.

Authors:  Ann M Geiger; Soe Soe Thwin; Timothy L Lash; Diana S M Buist; Marianne N Prout; Feifei Wei; Terry S Field; Marianne Ulcickas Yood; Floyd J Frost; Shelley M Enger; Rebecca A Silliman
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

3.  Effectiveness of radiation therapy in older women with ductal carcinoma in situ.

Authors:  Benjamin D Smith; Bruce G Haffty; Thomas A Buchholz; Grace L Smith; Deron H Galusha; Justin E Bekelman; Cary P Gross
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

4.  Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer.

Authors:  E Janschek; D Kandioler-Eckersberger; C Ludwig; S Kappel; B Wolf; S Taucher; M Rudas; M Gnant; R Jakesz
Journal:  Breast Cancer Res Treat       Date:  2001-05       Impact factor: 4.872

5.  True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management.

Authors:  T E Smith; D Lee; B C Turner; D Carter; B G Haffty
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-12-01       Impact factor: 7.038

6.  Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data.

Authors:  Michael E Stokes; David Thompson; Eduardo L Montoya; Milton C Weinstein; Eric P Winer; Craig C Earle
Journal:  Value Health       Date:  2008 Mar-Apr       Impact factor: 5.725

7.  Completion of adjuvant radiation therapy among women with breast cancer.

Authors:  Tomasz P Srokowski; Shenying Fang; Zhigang Duan; Thomas A Buchholz; Gabriel N Hortobagyi; James S Goodwin; Sharon H Giordano
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

8.  Identifying cancer relapse using SEER-Medicare data.

Authors:  Craig C Earle; Ann B Nattinger; Arnold L Potosky; Kathleen Lang; Rajiv Mallick; Mark Berger; Joan L Warren
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

9.  Using Medicare claims to identify second primary cancers and recurrences in order to supplement a cancer registry.

Authors:  Donna McClish; Lynne Penberthy; Amy Pugh
Journal:  J Clin Epidemiol       Date:  2003-08       Impact factor: 6.437

10.  Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer.

Authors:  Adnan Aydiner; Faruk Tas
Journal:  Trials       Date:  2008-07-29       Impact factor: 2.279

View more
  54 in total

Review 1.  Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival.

Authors:  Jessica Chubak; Denise M Boudreau; Heidi S Wirtz; Barbara McKnight; Noel S Weiss
Journal:  J Natl Cancer Inst       Date:  2013-08-12       Impact factor: 13.506

2.  Contralateral Breast Cancer Event Detection Using Nature Language Processing.

Authors:  Zexian Zeng; Xiaoyu Li; Sasa Espino; Ankita Roy; Kristen Kitsch; Susan Clare; Seema Khan; Yuan Luo
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

3.  Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage.

Authors:  Neetu Chawla; K Robin Yabroff; Angela Mariotto; Timothy S McNeel; Deborah Schrag; Joan L Warren
Journal:  Ann Epidemiol       Date:  2014-07-03       Impact factor: 3.797

4.  Challenges and opportunities in measuring cancer recurrence in the United States.

Authors:  Joan L Warren; K Robin Yabroff
Journal:  J Natl Cancer Inst       Date:  2015-05-12       Impact factor: 13.506

5.  Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management.

Authors:  Michael J Hassett; Hajime Uno; Angel M Cronin; Nikki M Carroll; Mark C Hornbrook; Debra Ritzwoller
Journal:  Med Care       Date:  2017-12       Impact factor: 2.983

6.  Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.

Authors:  Frank I Scott; Ronac Mamtani; Colleen M Brensinger; Kevin Haynes; Zelma C Chiesa-Fuxench; Jie Zhang; Lang Chen; Fenglong Xie; Huifeng Yun; Mark T Osterman; Timothy Beukelman; David J Margolis; Jeffrey R Curtis; James D Lewis
Journal:  JAMA Dermatol       Date:  2016-02       Impact factor: 10.282

7.  Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population.

Authors:  Lu Chen; Jessica Chubak; Denise M Boudreau; William E Barlow; Noel S Weiss; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-08-14       Impact factor: 4.254

8.  Validation in Alberta of an administrative data algorithm to identify cancer recurrence.

Authors:  Z F Cairncross; G Nelson; L Shack; A Metcalfe
Journal:  Curr Oncol       Date:  2020-06-01       Impact factor: 3.677

9.  Identification of abnormal screening mammogram interpretation using Medicare claims data.

Authors:  Rebecca A Hubbard; Weiwei Zhu; Steven Balch; Tracy Onega; Joshua J Fenton
Journal:  Health Serv Res       Date:  2014-06-28       Impact factor: 3.402

10.  Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts.

Authors:  Michael J Hassett; Debra P Ritzwoller; Nathan Taback; Nikki Carroll; Angel M Cronin; Gladys V Ting; Deb Schrag; Joan L Warren; Mark C Hornbrook; Jane C Weeks
Journal:  Med Care       Date:  2014-10       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.